In this article, we demonstrate that BRCA1 promoter methylation, analyzed in a large cohort of 1031 primary breast tumors, predicts improved breast cancer–specific survival outcomes in patients treated with cytotoxic chemotherapy. The gene discussed is BRCA1; the disease is breast carcinoma.